BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 22959722)

  • 1. MIF, CD74 and other partners in kidney disease: tales of a promiscuous couple.
    Sanchez-Niño MD; Sanz AB; Ruiz-Andres O; Poveda J; Izquierdo MC; Selgas R; Egido J; Ortiz A
    Cytokine Growth Factor Rev; 2013 Feb; 24(1):23-40. PubMed ID: 22959722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role for CD74 and CXCR4 in clathrin-dependent endocytosis of the cytokine MIF.
    Schwartz V; Krüttgen A; Weis J; Weber C; Ostendorf T; Lue H; Bernhagen J
    Eur J Cell Biol; 2012; 91(6-7):435-49. PubMed ID: 22014447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LPS-mediated cell surface expression of CD74 promotes the proliferation of B cells in response to MIF.
    Klasen C; Ziehm T; Huber M; Asare Y; Kapurniotu A; Shachar I; Bernhagen J; El Bounkari O
    Cell Signal; 2018 Jun; 46():32-42. PubMed ID: 29476963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MIF inhibits monocytic movement through a non-canonical receptor and disruption of temporal Rho GTPase activities in U-937 cells.
    DiCosmo-Ponticello CJ; Hoover D; Coffman FD; Cohen S; Cohen MC
    Cytokine; 2014 Sep; 69(1):47-55. PubMed ID: 25022961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MIF promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling.
    Klasen C; Ohl K; Sternkopf M; Shachar I; Schmitz C; Heussen N; Hobeika E; Levit-Zerdoun E; Tenbrock K; Reth M; Bernhagen J; El Bounkari O
    J Immunol; 2014 Jun; 192(11):5273-84. PubMed ID: 24760155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TWEAK increases CD74 expression and sensitizes to DDT proinflammatory actions in tubular cells.
    Valiño-Rivas L; Cuarental L; Grana O; Bucala R; Leng L; Sanz A; Gomez G; Ortiz A; Sanchez-Niño MD
    PLoS One; 2018; 13(6):e0199391. PubMed ID: 29924850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-dopachrome tautomerase in adipose tissue inflammation and wound repair.
    Kim BS; Tilstam PV; Hwang SS; Simons D; Schulte W; Leng L; Sauler M; Ganse B; Averdunk L; Kopp R; Stoppe C; Bernhagen J; Pallua N; Bucala R
    J Cell Mol Med; 2017 Jan; 21(1):35-45. PubMed ID: 27605340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and function of macrophage migration inhibitory factor in the pathogenesis of UV-induced cutaneous nonmelanoma skin cancer.
    Heise R; Vetter-Kauczok CS; Skazik C; Czaja K; Marquardt Y; Lue H; Merk HF; Bernhagen J; Baron JM
    Photochem Photobiol; 2012; 88(5):1157-64. PubMed ID: 22324658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex.
    Shi X; Leng L; Wang T; Wang W; Du X; Li J; McDonald C; Chen Z; Murphy JW; Lolis E; Noble P; Knudson W; Bucala R
    Immunity; 2006 Oct; 25(4):595-606. PubMed ID: 17045821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage Migration Inhibitory Factor (MIF)-Based Therapeutic Concepts in Atherosclerosis and Inflammation.
    Sinitski D; Kontos C; Krammer C; Asare Y; Kapurniotu A; Bernhagen J
    Thromb Haemost; 2019 Apr; 119(4):553-566. PubMed ID: 30716779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74.
    Lue H; Dewor M; Leng L; Bucala R; Bernhagen J
    Cell Signal; 2011 Jan; 23(1):135-44. PubMed ID: 20807568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compartmentalized protective and detrimental effects of endogenous macrophage migration-inhibitory factor mediated by CXCR2 in a mouse model of myocardial ischemia/reperfusion.
    Liehn EA; Kanzler I; Konschalla S; Kroh A; Simsekyilmaz S; Sönmez TT; Bucala R; Bernhagen J; Weber C
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2180-6. PubMed ID: 23868943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of macrophage migration inhibitory factor (MIF) and CD74, receptor for MIF, in rat bladder during persistent cyclophosphamide-induced inflammation.
    Vera PL; Wang X; Meyer-Siegler KL
    Exp Biol Med (Maywood); 2008 May; 233(5):620-6. PubMed ID: 18375833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MIF-2/D-DT enhances proximal tubular cell regeneration through SLPI- and ATF4-dependent mechanisms.
    Ochi A; Chen D; Schulte W; Leng L; Moeckel N; Piecychna M; Averdunk L; Stoppe C; Bucala R; Moeckel G
    Am J Physiol Renal Physiol; 2017 Sep; 313(3):F767-F780. PubMed ID: 28539339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage migration inhibitory factor (MIF) promotes cell survival and proliferation of neural stem/progenitor cells.
    Ohta S; Misawa A; Fukaya R; Inoue S; Kanemura Y; Okano H; Kawakami Y; Toda M
    J Cell Sci; 2012 Jul; 125(Pt 13):3210-20. PubMed ID: 22454509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage Migration Inhibitory Factor Mediates Proliferative GN via CD74.
    Djudjaj S; Lue H; Rong S; Papasotiriou M; Klinkhammer BM; Zok S; Klaener O; Braun GS; Lindenmeyer MT; Cohen CD; Bucala R; Tittel AP; Kurts C; Moeller MJ; Floege J; Ostendorf T; Bernhagen J; Boor P
    J Am Soc Nephrol; 2016 Jun; 27(6):1650-64. PubMed ID: 26453615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical CD74 and CXCR4, macrophage migration inhibitory factor (MIF) receptors, mediate bladder pain.
    Ye S; Ma F; Mahmood DFD; Meyer-Siegler KL; Menard RE; Hunt DE; Leng L; Bucala R; Vera PL
    PLoS One; 2021; 16(8):e0255975. PubMed ID: 34424927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving complexity of MIF signaling.
    Jankauskas SS; Wong DWL; Bucala R; Djudjaj S; Boor P
    Cell Signal; 2019 May; 57():76-88. PubMed ID: 30682543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage Migration Inhibitory Factor (MIF) as a Stress Molecule in Renal Inflammation.
    Kong YZ; Chen Q; Lan HY
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MIF and D-DT are potential disease severity modifiers in male MS subjects.
    Benedek G; Meza-Romero R; Jordan K; Zhang Y; Nguyen H; Kent G; Li J; Siu E; Frazer J; Piecychna M; Du X; Sreih A; Leng L; Wiedrick J; Caillier SJ; Offner H; Oksenberg JR; Yadav V; Bourdette D; Bucala R; Vandenbark AA
    Proc Natl Acad Sci U S A; 2017 Oct; 114(40):E8421-E8429. PubMed ID: 28923927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.